BioWorld

April 17, 2002

View Archived Issues

Pharmacyclics: New Phase III Sharpens Cancer Drug’s Focus

Pharmacyclics Inc. is planning a new Phase III trial of its cancer cell disrupter, Xcytrin, in the sector of patients for whom the drug seems to do the most good those with lung cancer that has metastasized to the brain. (BioWorld Today) Read More

Bacillus subtilis Pinch Hits For B. anthracis To Make Antibodies From Spore Targets For Vaccine

Read More

Hatch Expects Election-Year Debates On Health Care Bills

Read More

Syntonix Series B Gets $35.8M For Large-Molecule Delivery

Read More

Other News To Note

Read More

Correction

Read More

Plexxikon Raises $27M Privately For Scaffold Discovery System

Read More